Drug Sponsors

Pepscan and U.S. company to discover novel antibodies

Monday, January 7, 2013 09:29 AM

Pepscan Therapeutics, a developer of protein mimicry technologies based in The Netherlands, has entered into a multi-target research agreement with an undisclosed U.S.-based antibody discovery company. 

More... »

Gradalis closes $24M Series B financing to advance FANG personalized cancer vaccine

Friday, January 4, 2013 12:26 PM

Gradalis, a privately-held, fully-integrated biotech based in Dallas, Texas, has closed a $24 million Series B round of financing.

More... »

Labrys Biologics secures $31M financing, acquires antibody for chronic migraine from Pfizer

Friday, January 4, 2013 11:57 AM

Labrys Biologics, a development stage biotechnology company focused on chronic migraines, has completed a $31 million Series A financing from four leading venture capital firms: venBio, Canaan Partners, InterWest Partners and Sofinnova Ventures. With the close of the financing, Labrys has acquired RN-307 from Pfizer Inc., a phase II ready anti-CGRP humanized monoclonal antibody for the treatment of chronic migraine. In addition, Steven P. James has been appointed president and CEO.

More... »

Government backs small business with $8.1M funding boost

Friday, January 4, 2013 11:01 AM

The U.K. government is holding two new competitions, with a total of up to $8.1 million in funding, for small businesses who have ideas that can improve the experience for older people at the end of their life or improve the experience for people with mental health illnesses.

More... »

Biogen Idec to discontinue development of ALS drug

Friday, January 4, 2013 10:29 AM

Weston, Mass.-based Biogen Idec has decided to discontinue development of dexpramipexole in amyotrophic lateral sclerosis (ALS), after top-line results of EMPOWER, its phase III trial, did not meet its primary endpoint, a joint rank analysis of function and survival, and no efficacy was seen in the individual components of function or survival.

More... »

JHP Pharmaceuticals acquired By Warburg Pincus

Wednesday, January 2, 2013 02:28 PM

JHP Pharmaceuticals, a Parsippany, N.J.-based specialty pharmaceutical focused on sterile injectable products, has been acquired by an affiliate of Warburg Pincus, a leading global private equity firm focused on growth investing, for $195 million on a debt-free, cash-free basis. JHP's current management team will continue to hold an interest in the company. Additional terms of the transaction were not disclosed.

More... »

Abbott completes separation of research-based pharmaceuticals business

Wednesday, January 2, 2013 02:09 PM

Global healthcare company Abbott Laboratories has completed the separation of its research-based pharmaceuticals business, which became AbbVie, a new independent biopharmaceutical company. AbbVie began trading independently on the New York Stock Exchange on Jan. 2, 2013, under the symbol "ABBV."

More... »

Perrigo acquires remaining stake in Cobrek Pharmaceuticals

Wednesday, January 2, 2013 12:18 PM

Perrigo, a global provider of healthcare products, has signed a definitive merger agreement with Cobrek Pharmaceuticals, a Chicago-based, privately held drug development company, and has acquired the company for approximately $45 million on a cash free and debt free basis.

More... »

Elan completes demerger of Prothena

Friday, December 21, 2012 02:40 PM

Dublin-based Elan has completed the separation of a substantial portion of its drug discovery business (the Prothena Business) into a new independent, publicly traded company, Prothena. Incorporated in Ireland, Prothena commenced trading on the NASDAQ Global Market as of Dec. 21.

More... »

New company NeRRe Therapeutics created to develop neurokinin antagonists from GSK

Wednesday, December 19, 2012 10:42 AM

NeRRe Therapeutics, a new drug discovery company, has been launched to develop a portfolio of clinical and pre-clinical neurokinin receptor antagonists divested from GlaxoSmithKline (GSK).

More... »